We're the biggest medical cannabis raise on Seedrs EVER 🎉🎉
We've smashed through our £3.2m fundraise target and we're still going! We're the largest raise on Seedrs at the moment, and their biggest cannabis raise of all time!
A newsletter all about cannabis medicines, that offers patient and business perspectives, written by the team at Grow.
🌱 This week, in the world of cannabis medicine:
→ Employee intro: Meet our Head of Material Science, Sadaf!
→ Grow updates: A history making crowdfund 🎉
→ Patient perspectives: Louise’s Story
→ Tips to Grow
Hi everyone - another week, another newsletter! I’m Dr Sadaf, Head of Material Science here at Grow.
As more people join the community, following our amazing first week of public crowdfunding, I thought it would be a good time to explain more about Grow’s incredible research & development (R&D) work.
R&D is crucial to our mission here at Grow and fundamentally, it’s about laying the groundwork for new cannabis medicines that could change patients’ lives!
Day to day, my team and I carry out clinical research into post-extraction technologies, which we’ve already filed a couple of patents for. With your investment, we can continue this work so we can help more people like Louise, whose story you’ll get to read below.
That’s why I’m so grateful to all of you that have invested already. Your support will help us change the landscape of medical cannabis.
Enjoy this week’s newsletter and remember - you can always join our community and help improve access to cannabis medicines through our crowdfund!
→ 🚨 Crowdfund update: It’s been a truly historic week for our crowdfund; we opened to the public after our pre-registration phase, and currently have over £3.2m raised 👏 That makes us not only the largest cannabis raise on Seedrs ever, but also the largest raise on Seedrs at the moment. THANK YOU to each and every one of you who has supported us this far! We’re still taking investment and will let you know before we close the round - until then, you can invest here.
→ 📰 In the News: Watch our very own Community & Investor Relations Lead, Hannah Nommé, in action as she’s interviewed by leading investment media outlet, Proactive London! Watch Hannah’s interview below to hear more about our story, and the future of the company 🖥️
“I’ve had arthritis all my life, and have been in chronic pain for over 20 years. I had tried (and exhausted) every avenue of pain relief from physio and massage to steroid and nerve root injections and surgery.
“Eventually, after pushing my pain consultant for five years, he agreed to a medical cannabis prescription.
“Before, I would spend endless days propped up in bed with chronic pain, making me feel anxious and guilty that I couldn’t spend time with my three grandchildren. Now, I can wake up from a good night’s sleep feeling rested, control the anxiety I feel from pain, and spend quality time with those I love planting vegetables in the garden.
“I want nothing more than cannabis medicines being brought into mainstream conversation - it will be easier and fairer for patients to access and feel comfortable speaking to family and friends about it. It’s been a very rewarding journey for me so far, and I hope it continues.”
Tips to Grow 💪
🌱 Get daily news, community chat & crowdfunding updates on Twitter & LinkedIn.
🌱 Want to knowledge share with us? You can drop us a note here.
🌱 Share with your pals and tell them about the massive positive potential of cannabis medicines.
Thanks for reading, see you next week 👋👋👋
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future. Seedrs does not make investment recommendations to you and any investment decision should be made on the basis of the full campaign. No communications from Seedrs, through email or any other medium, should be construed as an investment recommendation.
This email has been approved as a financial promotion by Seedrs Limited.